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RESECTION FOR BARRETT'S MUCOSA WITH HIGH-GRADE DYSPLASIA: IMPLICATIONS FOR 
PROPHYLACTIC PHOTODYNAMIC THERAPY 
Mark K. Ferguson, MD a 
Keith S. Naunheim, MD b 
Objectives: Optimal therapy for Barrett's mucosa is controversial. Photody- 
namic therapy has recently been introduced as a technique for eradicating 
Barrett's mucosa with high-grade dysplasia. We sought to determine the 
incidence of invasive cancer and the outcomes after resection for high- 
grade dysplasia and to compare these results with published results of 
photodynamic therapy. Methods: We performed a retrospective r view of 
patients who underwent esophagectomy for Barrett's esophagus from 1985 
to 1996 and completed a metaanalysis of published results of surgery for 
Barrett's esophagus with high-grade dysplasia. Results: Thirteen men and 
two women with a mean age of 63 years underwent resection for Barrett's 
esophagus with high-grade dysplasia. The operation was performed 
through a transhiatal approach in nine and a transthoracic approach in six 
patients. There was no operative mortality. The final pathologic study 
demonstrated dysplasia in four patients, carcinoma-in-situ in three, and 
invasive carcinoma in eight patients (53%). All patients are alive and none 
of the patients with invasive cancer has recurrent disease. A metaanalysis 
of published results of 119 patients undergoing resection demonstrated an 
operative mortality of 2.6%, an incidence of invasive cancer of 47%, and a 
5-year survival in patients with invasive carcinoma of 82%. Conclusions: A 
substantial percentage ofpatients with Barrett's mucosa containing foci of 
high-grade dysplasia have invasive carcinoma t the time of diagnosis. 
Resection is accompanied by a low operative risk, achieves an excellent 
long-term outcome, and should remain the standard therapy for Barrett's 
esophagus with high-grade dysplasia. (J Thorac Cardiovasc Surg 1997;114: 
824-9) 
O Ptimal therapy for patients with Barrett's esoph- agus with dysplasia is controversial. The finding 
of low-grade dysplasia usually is little cause for 
concern because the immediate risk of an invasive 
cancer is minimal and because the likelihood of 
progression to cancer, while not accurately calcu- 
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lated, is likely to be very low. In contrast, the finding 
of high-grade dysplasia precipitates a wide variety of 
responses, including increased frequency of endo- 
scopic surveillance, esophageal resection, and, re- 
cently, photodynamic therapy (PDT). Although 
some centers claim to be able to reliably distinguish 
between patients with high-grade dysplasia who are 
at risk for the development of invasive cancer and 
those whose risk is low, ~ there is no general agree- 
ment that this approach is acceptable. Instead, many 
groups recommend resection for healthy patients 
with Barrett's esophagus containing high-grade dys- 
plasia because of the concern that a high proportion 
of such patients have an unsuspected invasive ade- 
nocarcinoma. 
Concern over the incidence of "unnecessary" 
esophageal resections has stimulated the use of laser 
therapy, both as a thermal medium and in the form 
of PDT, in the eradication of Barrett's mucosa. 2-6 
Recent reports suggest that PDT combined with 
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Table I. Results of surgical therapy for Barrett's esophagus with high-grade dysplasia 
No. of Stage 
Author Year patients Mortality I Ila IIb III IV  Carcinoma Recurrence 
DeMeester et al. 14 1990 2 * 1 0 0 0 0 
Altorki et al. 15 1991 8 0 3 1 0 0 0 
McArdle et al. 16 1992 3 * 2 0 0 0 0 
Pera et al. 17 1992 18 0 6 2 1 0 0 
Rice et al. 18 1993 16 1 6 0 0 0 0 
Levine et al. a 1993 7 1 0 0 0 0 0 
Peters et al. 19 1994 9 0 4 1 0 0 0 
Edwards et al. 2° 1996 11 0 4 2 0 2 0 
Heitmiller et al. 21 1996 30 1 8 4 0 1 0 
Ferguson and 1997 15 0 7 1 0 0 0 
Naunheim 











56 (47%) 5 (9%) 
intensive pharmacologic acid suppression results in 
the replacement of columnar mucosa with squa- 
mous mucosa and that this treatment may be rela- 
tively specific for regions of high-grade dysplasia. 7-1° 
However, there is a strong potential for inadequate 
therapy of PDT for Barrett's mucosa with high-grade 
dysplasia because of the presence of residual columnar 
mucosa and, in some patients, residual high-grade 
dysplasia. This problem prompted us to review our 
results of resection for Barrett's mucosa with high- 
grade dysplasia. We also performed a metaanalysis of
outcomes for resection to permit an accurate charac- 
terization of this treatment modality so that these 
results can be compared with results of PDT. 
Methods 
We performed a retrospective r view of patients who 
underwent esophagectomy for Barrett's esophagus at The 
University of Chicago Medical Center and at St. Louis 
University Medical Center from 1985 through 1996. Pa- 
tients were chosen for further eview who had a preoper- 
ative diagnosis of high-grade dysplasia or carcinoma-in- 
situ on the basis of endoscopic biopsy results and who had 
no endoscopic or histologic evidence for invasive cancer 
before the operation. High-grade dysplasia nd carcino- 
ma-in-situ were classified according to previously estab- 
lished criteria. 11 Preoperative characteristics, periopera- 
tive data, and postoperative outcomes were recorded. 
Staging was performed according to the TNM system of 
the American Joint Committee on Cancer. 12 Individual 
patient status as of April 1997 was identified by outpatient 
records, patient examination, or telephone interview. 
Data were expressed as mean _+ standard error of the 
mean. 
We identified English language reports that described 
surgical therapy for Barrett's esophagus with high-grade 
dysplasia published from 1990 through 1996 and summa- 
rized indications for and outcome of these interventions. 
A metaanalysis of outcomes for surgical resection was 
performed and overall survival was calculated. 13
Results 
During the study period, 107 patients with Bar- 
rett's esophagus underwent resection. Of these, 15 
were operated on for a preoperative diagnosis of 
high-grade dysplasia. The patients comprised 13 
men and two women with a mean age of 63 _+ 3 
years (range 35 to 76 years). In contrast to the usual 
patient undergoing resection, these patients rarely 
reported dysphagia as a primary complaint, and 
their mean preoperative weight loss was 1.3 _+ 0.6 
kg. 
No patient received preoperative radiotherapy 
or chemotherapy. The operation was performed 
through a transhiatal approach in nine patients, 
through a left thoracotomy with an intrathoracic 
anastomosis in three, through a left thoracotomy 
with a cervical anastomosis n two, and by means of 
h modified Ivor Lewis approach with a cervical 
anastomosis n one patient. In all patients the entire 
segment of Barrett's mucosa was resected. 
Reconstruction was accomplished with the stom- 
ach in 13 patients and with a colon interposition in 
two patients. The mean intraoperative blood loss 
was 715 _+ 150 ml and the average intraoperative 
transfusion requirement was 1.3 _+ 0.5 units of 
packed red blood cells. 
No operative or hospital deaths occurred. Four 
patients had anastomotic leaks, all of which healed 
without major reoperation. The overall incidence of 
complications was 73% (11/15) and included pulmo- 
nary complications in four patients, cardiovascular 
complications in three, infectious complications in 
five, and other surgical complications in five pa- 
tients. The mean length of postoperative hospital 
stay was 18.5 _+ 3.0 days and the median length of 
stay was 16 days. 
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Fig. 1. Actuarial survival (including operative mortality) 
in patients found to have invasive adenocarcinoma after 
resection for high-grade dysplasia in Barrett's esophagus. 
Vertical bars depict standard error, and numbers in paren- 
theses represent the number of patients at risk at each 
time interval. The probability of survival at 5 years is 82%. 
The final pathologic diagnoses in these patients 
revealed ysplasia only in four patients, carcinoma- 
in-situ in three, and invasive cancer in eight patients 
(53%; stage T1 NO M0 in seven patients and T3 NO 
M0 in one patient). At a mean follow-up of 41 _+ 9 
months the median survival has not been reached 
and no instances of cancer recurrence have been 
verified. 
We identified nine additional reports of surgical 
therapy for Barrett's esophagus with high-grade 
dysplasia published in English from 1990 to 
1996.1, 14-21 A total of 119 patients were analyzed, of 
whom 56 (47%) were found to have invasive adeno- 
carcinoma in the resected specimens (Table I). The 
operative mortality was 2.6% (3/114). Although the 
majority of patients had stage I cancer, 15 (27%) of 
those patients with cancer had stage IIa or more 
advanced tumors. With a mean follow-up of 38 
months, the cancer recurrence rate was 9% (5/53) 
among patients with invasive cancer and was 5% 
(2/41) among patients with stage I cancer. The 
5-year overall survival was 82% (Fig. 1). 
Discussion 
Barrett's esophagus i a mucosal disorder charac- 
terized by a histologic progression from metaplasia 
through dysplasia and finally to invasive cancer. 
About 10% of persons with moderate-to-severe 
chronic reflux symptoms have Barrett's mucosa, and 
about 10% of individuals with Barrett's mucosa but 
without invasive adenocarcinoma have dysplastic 
epithelium. Considering that more than 20 million 
individuals in North America have reflux symptoms, 
the problem of dysplasia is potentially large. As 
such, it has been studied extensively in an effort to 
identify markers that indicate which patients have 
dysplasia that is most likely to progress to invasive 
cancer. Such biochemical and genetic markers in- 
clude the loss of O-acetylated sialomucins, the pres- 
ence of sucrase isomaltase, an increase in nucleolar 
organizer egions, a rise in G2 phase percentages, 
the presence of aneuploidy, and evidence for p53 
mutations. However, the promise of early detection 
of patients at high risk has yet to be realized. 22-24 No 
one has yet found a reliable means to predict which 
patients have dysplasia that will progress to malig- 
nant degeneration a d thus should undergo prophy- 
lactic or early therapeutic ntervention. 
The best current means of assessing risk is the 
histologic or cytologic identification of high-grade 
dysplasia. Although expert pathologists sometimes 
disagree about he differentiation between low- and 
high-grade dysplasia nd about whether high-grade 
dysplasia and carcinoma-in-situ can be distin- 
guished, all agree that high-grade dysplasia is a 
premalignant lesion. Unfortunately, some patients 
with high-grade dysplasia lready have invasive ad- 
enocarcinoma. The prevalence of invasive carci- 
noma among patients who undergo resection 
for high-grade dysplasia approaches 50%, 1'14-21 
whereas the incidence of progression from high- 
grade dysplasia to invasive carcinoma was reported 
to be about 26% during a median follow-up period 
of 2 years. 25 The discrepancy between these two 
figures may be explained in part by the fact that 
some patients who are referred for resection of 
high-grade dysplasia have other endoscopic findings 
such as raised mucosal esions that increase the 
likelihood of finding invasive cancer. In addition, 
the time course of progression from dysplasia to 
invasive cancer is poorly understood. The histo- 
logic sampling of a resected specimen that reveals 
invasive cancer is more complete than that possi- 
ble in endoscopic biopsies, yielding lower esti- 
mates for the frequency of progression from high- 
grade dysplasia to invasive carcinoma in patients 
undergoing surveillance than in those referred for 
resection. 
Endoscopic ultrasonography is sometimes useful 
in assessing the depth of penetration of the esoph- 
ageal tumors. By logical extension, endoscopic ul- 
trasonography as found favor in some centers as a 
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Table II. Results of PDT for Barrett's esophagus with HGD 
Residual 
Photoactive No. of Follow-up Residual Barrett's 
Author Year compound patients (mo) Stricture HGD esophagus 
Laukka and Wang s 1995 Hematoporphyrin 5 2-12 0 0/1 5/5 
derivative 
Barr et al. 9 1996 Protoporphyrin IX 5 26-44 0 0/5 4/5 
Overholt and 1996 Porfimer sodium 36 2-62 21 2/17 10/36 
Panjehpour l° 
Totals 46 21 (46%) 2/23 (9%) 19/46 (41%) 
PDT, Photodynamic therapy; HGD, high-grade dysplasia. 
means to assess patients with Barrett's esophagus 
containing areas of dysplasia. Unfortunately, the 
accuracy of endoscopic ultrasonography is greatest 
for grossly evident esophageal cancers and is poor- 
est when relatively superficial lesions are studied. In 
one preliminary study of patients with Barrett's 
esophagus, mean mucosal thickness as measured by 
endoscopic ultrasonography was not different be- 
tween patients with dysplastic and those with non- 
dysplastic Barrett's mucosaY Another preliminary 
study demonstrated both overestimations and un- 
derestimations of the depth of extent of mucosal 
abnormalities and concluded that endoscopic ultra- 
sonography does not reliably distinguish between 
benign and malignant wall thickening in patients 
with Barrett's mucosa. 27 
Because of the lack of definitive information, a
number of centers recommend that patients with 
Barrett's esophagus containing high-grade dysplasia 
or carcinoma-in-situ undergo resection of the Bar- 
rett's segment because of the high risk of invasive 
cancer and the favorable surgical outcomes. Our 
metaanalysis demonstrates anoperative mortality in 
these highly selected patients of less than 3% and a 
5-year survival of more than 80%, even when the 
disease had advanced beyond stage I in more than 
25% of patients. Resection of the entire Barrett's 
segment also eliminates the need for routine surveil- 
lance endoscopy. 
Despite these good surgical results, several cen- 
ters are now involved in the use of PDT for the 
management of Barrett's esophagus with high-grade 
dysplasia or early invasive adenocarcinoma. The 
rationale is that PDT targets regions of high-grade 
dysplasia nd invasive cancer, selectively eliminating 
threatening regions in the mucosa without he need 
for resection, while concurrent intense acid suppres- 
sion permits resurfacing of the affected esophagus 
with squamous mucosa. The published results of 
preliminary efforts are encouraging but by no means 
demonstrate hat PDT has a clear advantage over 
resection in the management of high-grade dyspla- 
sia. Among 46 cases reported to date, the follow- 
up has been relatively short, averaging less than 2 
years 8-1° (Table II). The incidence of benign stric- 
ture necessitating dilation is almost 50%, suggesting 
that functional results are not optimal despite 
esophageal preservation. Of greater concern is the 
fact that more than 40% of patients have residual 
Barrett's mucosa, which is theoretically at risk for 
the development of new regions of dysplasia. Fi- 
nally, almost 10% of patients have residual areas of 
high-grade dysplasia, indicating that these initial 
attempts at eradicating columnar mucosa with high- 
grade dysplasia re only partially successful. As a 
result, patients who undergo PDT for high-grade 
dysplasia need to be maintained on an intense acid 
suppression regimen indefinitely and continue to 
require surveillance ndoscopy at regular intervals. 
What of the patients treated with PDT whose 
disease is understaged and who have invasive cancer 
or lymph node involvement, a subgroup that made 
up more than 25% of patients undergoing resection 
for high-grade dysplasia? The depth of penetration 
of PDT is dependent on, among other factors, the 
wavelength of laser energy and the techniques used 
to diffuse the energy into the tissues. The net result 
is an unpredictable and uncontrollable degree of 
tissue penetration, with no guarantee that the full 
depth of the primary tumor will be treated, much 
less that any effect will be evident in regional lymph 
nodes. 
Alternatives to esophagectomy and PDT exist for 
management of Barrett's esophagus with high-grade 
dysplasia. These include eradication of Barrett's 
mucosa with thermal coagulation, such as electro- 
cautery or neodymium:yttrium-aluminum-garnet l - 
ser therapy combined with intense acid suppression 
accomplished by fundoplication or pharmacologic 
means. The high frequency of nonfatal periopera- 
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tive complications associated with esophagectomy 
and the risk of long-term disabling symptoms in 
some patients owing to postvagotomy syndrome, 
dumping, and other gastrointestinal motor disorders 
make the pursuit of such alternative therapies ap- 
pealing. However, long-term data on the results of 
such treatments are currently lacking. 
As a result of these findings, we conclude that 
resection of the Barrett's segment should be stan- 
dard therapy for Barrett's esophagus with high- 
grade dysplasia or carcinoma-in-situ in patients with 
acceptable physiologic risk. This operation is per- 
formed routinely with acceptable operative mortal- 
ity and excellent long-term survival. Resection elim- 
inates the need for surveillance ndoscopy and acid 
suppression medications in most patients. In con- 
trast, PDT requires long-term acid suppression and 
continued surveillance and fails to reliably eliminate 
high-grade dysplasia. Optimal candidates for PDT 
may be those individuals who are at high risk for 
resection, in whom the risk of malignant degenera- 
tion may be reduced with this technique. Otherwise, 
until additional data and longer-term follow-up are 
available, the use of PDT for Barrett's esophagus 
with high-grade dysplasia should remain investiga- 
tional. 
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Discussion 
Dr. Nasser K. AItorki (New York, N.Y.). Dr. Ferguson 
and Dr. Naunheim present us with conclusions with which 
we have no disagreements: (1) that high-grade dysplasia is
a premalignant lesion; (2) that it is the best available 
marker for an associated invasive cancer; and (3) that 
resection yields excellent long-term results. 
Despite the fact that no hospital deaths occurred in this 
series, esophagectomy is definitely associated with a finite 
mortality and a substantial morbidity, 73% in this series, 
with a median hospital stay of 16 days. Additionally, the 
patients who are discharged from the hospital without 
morbidity never quite regain the normal swallowing or the 
normal dietary habits that they would enjoy should their 
native esophagus be retained. Finally, almost 50% of the 
patients do undergo an unnecessary esophagectomy. The 
problem is that we cannot predict hat ahead of time. A 
modality that may eradicate the tumor with a minimal 
morbidity, a short hospital stay, and retention of the 
native esophagus i an attractive proposition. 
PDT with its limited penetration of approximately 5 
mm to 10 mm may be ideally suited for the treatment of 
the intramucosal cancers that are often associated with 
high-grade dysplasia. Your data show that 75% of the 
tumors were T1 lesions, but T1 lesions can range from 
deep submucosal cancers to intramucosal cancers that 
breach the basement membrane but are limited by the 
muscularis mucosa. In our experience these account for 
about 75% of the actual invasive T1 lesions. Deeper 
tumors obviously do occur, and they are a concern be- 
cause PDT would not get deep enough and the prevalence 
of nodal metastases would rise. However, endoscopic 
ultrasonography done before resection might detect hose 
deeper tumors and obviate the need for PDT. Although 
strictures do occur with PDT, they are generally respon- 
sive to dilation. Furthermore, the esophagogastric anas- 
tomosis, particularly if done in the neck, will usually not 
require one or two sessions of dilation done after the 
operation. 
The other issue that arises concerns the eradication of 
the dysplastic mucosa in patients without an associated 
invasive cancer. While clearly that is dramatically achieved 
by an esophagectomy, it seem almost tantamount o 
reaching for a shotgun to kill a fly. Dysplastic mucosa can 
be eradicated in a significant percentage of patients 
treated by PDT. In some cases the metaplastic columnar 
epithelium is buried underneath the regenerating squa- 
mous mucosa in the same manner that we sometimes see 
after antireflux surgery. The long-term effect of that 
submerged metaplastic mucosa in either case, after anti- 
reflux surgery or PDT, will obviously remain unknown for 
some time. 
I agree with you that PDT is an investigative modality 
whose role has yet to be defined, but I would like to ask 
two questions. Do you think that PDT may be applicable 
in the cases of intramucosal cancers? The precedent has 
been set by some Japanese surgeons practicing mucosec- 
tomy for early intramucosal squamous cell cancer of the 
esophagus with apparently some good results. Second, do 
you see a role for PDT in eradicating metaplastic or 
dysplastic mucosa in patients without cancer at all? 
Dr. Ferguson. I agree with you on most of your points. 
Your primary point was that one could theoretically use 
endoscopic ultrasonography to help decide which of the 
patients with Barrett's esophagus and dysplasia should 
receive a less aggressive form of therapy that can eradicate 
the mucosa versus those that need to have resectional 
treatment. Unfortunately, the published experience to 
date does not bear out that ability. The Cleveland Clinic 
has shown that endoscopic ultrasonography is not very 
accurate in assessing Barrett's mucosa. Much more expe- 
rience must be gained before endoscopic ultrasonography 
will be useful for that. 
I am hopeful for the future that we will find something 
other than an esophagectomy to treat these very early- 
stage tumors. I am also optimistic about the future of 
PDT. What I am concerned about is that its current use is 
inappropriate outside of a study and it is being adopted by 
many gastroenterologists as an accepted treatment for this 
condition. What we wanted to do was to present some of 
the aggregate experience to show that we are doing a very 
good job with our current echniques. We also wished to 
sound the warning that PDT may be used indiscriminately 
in some patients. Much more must be learned about PDT 
before it can be useful in a standard fashion for these 
patients. 
Dr. Joe B. Putnam, Jr. (Houston, Tex.). Dr. Ferguson, I 
agree with your conclusions that esophagectomy for high- 
grade dysplasia is appropriate for this disease. We re- 
viewed the cases of 29 patients over a 10-year period with 
Barrett's esophagus in a nonsurveillance program; 75% 
had invasive carcinoma nd two had positive nodes. How 
would you view treating patients with PDT in a surveil- 
lance program? These programs would typically have an 
ongoing surveillance in these individuals, the mucosal 
changes would be identified early, and these patients 
would be prime candidates. Don't you think that this 
would also be an appropriate population in which to study 
this evolving technique? 
Dr. Ferguson. I agree. It would be a very good group to 
study as an investigational effort. Unfortunately, what we 
have shown here is that the current echnology for PDT, 
including the laser wavelength, the photosensitizer, and 
the laser diffusion system, is not perfected, and so under- 
penetration is a problem in some areas. The result is 
incomplete radication of the Barrett's mucosa and in- 
complete eradication of the high-grade dysplasia. By 
definition, all of the patients who undergo PDT should 
continue with a surveillance program. That would be a 
good setting in which to investigate PDT. 
